POLYMER COMPOSITIONS, COATINGS AND DEVICES, AND METHODS OF MAKING AND USING THE SAME

• US 20090287072A1
• Filed: 12/01/2006
• Published: 11/19/2009
• Est. Priority Date: 12/02/2005
• Status: Abandoned Application

• Current Assignee: Accord Biomaterials, Inc.
• Original Assignee: Michigan Critical Care Consultants, Inc., Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Hwang, Sang-Yeul, Meyerhoff, Mark E., Reynolds, Melissa M., Cha, Wansik
• Application Number:
  US12/095,656
• Publication Number:
  US 20090287072A1
• Time in Patent Office: Days
• US Class Current: 600/345
• CPC Class Codes: A61L 17/005 containing a biologically active substance, e.g. a medicament or a biocide
• CPC Class Codes: A61L 17/145 Coating
• CPC Class Codes: A61L 2300/254 Enzymes, proenzymes
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 27/30 Inorganic materials
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/10 Inorganic materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/082 Inorganic materials
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61L 33/0047 Enzymes, e.g. urokinase, streptokinase
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The disclosure provides for a biocompatible, thromboresistant coating including a chalcogenide compound that induces nitric oxide formation; and a biocompatible matrix incorporating the chalcogenide compound. Devices incorporating such coatings, and methods of making and using such coatings are also disclosed herein.

Claims

1. A biocompatible, thromboresistant coating for use on an implantable medical device, comprising:

a chalcogenide compound that induces nitric oxide formation; and

a biocompatible matrix incorporating said chalcogenide compound.

2. The coating of claim 1, wherein said chalcogenide compound is selected from of an organoselenium compound and an organotellurium compound.

3. The coating of claim 2, wherein said chalcogenide compound is selected from:

an enzyme comprising selenium and an enzyme comprising tellurium.

4. The coating of claim 1, wherein said matrix comprises a polymer.

5. The coating of claim 4, wherein said polymer includes one or more of:

a carboxyl moiety, an aldehyde moiety, or a halide moiety.

6. The coating of claim 4, wherein said polymer comprises more than about 0.6 mmol/g carboxyl moieties.

7. The coating of claim 4, wherein said polymer is hydrophilic.

8. The coating of claim 4, wherein said polymer is selected from:

polyurethane, polyester, polyethyleneimine, polymethacrylate, polytetrafluoroethylene, and polydimethylsiloxane.

9. The coating of claim 1, wherein said matrix further comprises a therapeutic agent.

10. The coating of claim 1, wherein said chalcogenide compound comprises a carboxyl moiety or an amine moiety.

11. The coating of claim 1, wherein said chalcogenide compound is disposed on a surface of said matrix.

12. The coating of claim 4, wherein said chalcogenide compound is covalently bound to said polymer.

13. The coating of claim 1, wherein said matrix comprises a porous membrane structure, a fibrous matrix, or fumed silica.

14. The coating of claim 2, wherein said organoselenium moiety is selected from selenocystamine, selenocystine, 3,3′

-diselenodipropionic acid, selenocysteine, ebselen, propyl-selenocystine, allyl-selenocystine, methyl-selenocystine, selenomethionine, selenium choline, a diselenium compound, and combinations thereof.

15. The coating of claim 3, wherein said enzyme comprising selenium is selected from glutathione peroxidase and a selenocysteine-containing thioredoxin.

16. The coating of claim 1, which decomposes nitrosothiols to generate nitric oxide.

17. The coating of claim 1, further comprising a separate layer from said matrix, said matrix including a first polymer and said separate layer comprising a second polymer.

18. The coating of claim 17, wherein said second polymer is hydrophilic.

19. The coating of claim 17, wherein said separate layer further comprises a therapeutic agent.

20. The coating of claim 1, disposed on a medical device, wherein the medical device is selected from:

a suture, a vascular implant, a stent, a stent graft, a heart valve, a drug pump, a sensor, a drug delivery catheter, an infusion catheter, and a drug delivery guidewire.

28. A biocompatible implantable analyte sensor, comprising:

an electrode surface and disposed thereon an at least partially analyte-permeable coating of claim 1.

29. The analyte sensor of claim 28, wherein said sensor is subcutaneously implantable.

30. The analyte sensor of claim 28, wherein said sensor is intravascularly implantable.

31. The analyte sensor of claim 28, wherein said sensor detects nitrosothiol.

32. A method for treating a cardiovascular disease or disorder in a patient in need thereof, the method comprising implanting a device to access blood flow or tissue, wherein said device comprises a coating of claim 1.

33. The method of claim 32, wherein the cardiovascular disease or disorder is restenosis, coronary artery disease, atherosclerosis, atherogenesis, cerebrovascular disease, angina, ischemic disease, congestive heart failure, pulmonary edema associated with acute myocardial infarction, thrombosis, high or elevated blood pressure in hypertension, platelet aggregation, platelet adhesion, smooth muscle cell proliferation, a vascular or non-vascular complication associated with the use of a medical device, a wound associated with the use of a medical device, vascular or non-vascular wall damage, peripheral vascular disease or neoinitimal hyperplasia following percutaneous transluminal coronary angiograph.

34. The method of claim 32, wherein the cardiovascular disease or disorder is restenosis or atherosclerosis.

35. The method of claim 33, wherein the medical device is selected from a suture, a vascular implant, a stent, a stent graft, a heart valve, a drug pump, a drug delivery catheter, an infusion catheter and a drug delivery guidewire.

36. The method of claim 32, comprising the additional step of administrating an anti-infective agent.

39. A medical device comprising the composition of or the coating of claim 1.

40. The medical device of claim 39, wherein the medical device is selected from an intravascular or extravascular medical device, a balloon, a catheter tip, a prosthetic heart valve, a suture, a surgical staple, a synthetic vessel graft, a stent, a stent graft, a vascular or non-vascular graft, a shunt, an aneurysm filler, an intraluminal paving system, a guide wire, an embolic agent, a filter, a drug pump, an arteriovenous shunt, an artificial heart valve, an artificial implant, a foreign body introduced surgically into the blood vessels or at a vascular or non-vascular site, a lead, a pacemaker, an implantable pulse generator, an implantable cardiac defibrillator, a cardioverter defibrillator, a defibrillator, a spinal stimulator, a brain stimulator, a sacral nerve stimulator, a chemical sensor, an interventional cardiology device, a catheter, and plastic tubing.

41. A method for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device comprising implanting the medical device of claim 39 into a patient.

42. A method of promoting angiogenesis in a subject afflicted with atherosclerosis, comprising implanting the medical device of claim 39 to said subject at a tissue locus experiencing or at risk of insufficient blood perfusion.

21. A composition for use in association with a bioimplant, the composition comprising a matrix covalently bound to a chalcogenide moiety;

wherein said chalcogenide moiety is selected from an organoselenium moiety and an organotellurium moiety.

22. The composition of claim 21, wherein said organoselenium moiety is a diselenium moiety.

23. The composition of claim 21, wherein said organotellurium moiety is a ditellurium moiety.

24. The composition of claim 21, wherein said chalcogenide moiety comprises a moiety selected from structure I or II:

25. The composition of claim 21, wherein the matrix comprises a polymer moiety.

26. The composition of claim 25, wherein said polymer moiety comprises polyurethane, polyester, polyethyleneimine, polymethacrylate, polytetrafluoroethylene, or polydimethylsiloxane.

27. The composition of claim 21, wherein the matrix comprises a fibrous matrix or fumed silica.

37. A method for direct delivery of nitric oxide to a targeted site in a patient in need thereof, the method comprising implanting the composition of claim 21 directly to the targeted site in the patient.

38. The method of claim 37, wherein the composition provides sustained delivery of nitric oxide to the targeted site in the patient.

43-44. -44. (canceled)